Serum Vascular Endothelial Growth Factor C Correlates With Lymph Node Metastases and High-Risk Tumor Profiles in Papillary Thyroid Carcinoma
- 1 March 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 247 (3) , 483-489
- https://doi.org/10.1097/sla.0b013e31815fa447
Abstract
Objective: To evaluate the clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in papillary thyroid carcinoma (PTC). Summary Background Data: VEGF is a potent angiogenic factor promoting tumor angioinvasion and distant metastases, whereas VEGF-C enhances nodal metastases because of its lymphangiogenic effect. Although both tissues VEGF and VEGF-C have been shown to contribute to tumor metastases in PTC, the clinical relevance of serum VEGF (sVEGF) and sVEGF-C remains unknown. Methods: Preoperative serum samples collected from 85 primary PTC patients and 44 control subjects with benign thyroid diseases were measured for sVEGF and sVEGF-C levels. Potential correlations between their serum levels and clinicopathologic features as well as the commonly adopted risk group stratification profiles of the tumors were analyzed. Results: Preoperative sVEGF and sVEGF-C levels of PTC patients were significantly higher compared with those of control subjects (P = 0.001 and P < 0.001, respectively). sVEGF-C level was significantly elevated in older patients, those with extrathyroidal invasion and with lymph node metastases whereas sVEGF level was significantly increased in multifocal tumors. sVEGF-C, but not sVEGF, correlated significantly with high risk tumors in all commonly adopted risk group stratification profiles. An elevated preoperative sVEGF-C level of >7200 pg/mL was shown to be the only independent risk factor for nodal metastases. sVEGF-C levels declined significantly at 3 months after thyroidectomy in PTC but not control patients. Conclusions: sVEGF-C levels in PTC patients correlated significantly with the presence of nodal metastases and advanced tumor stages. Its clinical relevance needs further evaluation.Keywords
This publication has 39 references indexed in Scilit:
- Vascular Endothelial Growth Factor-C Accelerates Diabetic Wound HealingThe American Journal of Pathology, 2006
- Vascular Endothelial Growth Factor–C (VEGF-C) Expression in Normal Human TissuesLymphatic Research and Biology, 2006
- Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node MetastasesClinical Cancer Research, 2005
- Serum vascular endothelial growth factor (VEGF) and VEGF‐C levels as tumor markers in patients with cervical carcinomaCancer, 2005
- Lymphangiogenesis and CancerCancer Research, 2004
- A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up periodSurgery, 2004
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic MiceScience, 1997
- Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancerSurgery, 1996
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993